CHAPTER 46 Malignant Hyperthermia and Other Motor Diseases
3 Describe the cellular events, presentation, and metabolic abnormalities associated with malignant hyperthermia
4 How is malignant hyperthermia treated?



6 How is malignant hyperthermia susceptibility assessed in an individual with a positive family history or prior suggestive event?
7 What are the indications for muscle biopsy and halothane-caffeine contracture testing?

9 Describe the preparation of an anesthetic machine and anesthetic for a patient with known malignant hypothermia susceptibility
11 What patients are at risk for redeveloping symptoms of malignant hypothermia after treatment with dantrolene?
12 What drugs commonly administered intraoperatively are safe to use in malignant hyperthermia–susceptible patients
15 What are the most common muscular dystrophies and their clinical history?
Becker MD has similar, although milder, symptoms and a more protracted course.
25 What are some of the principal anesthetic concerns in the management of a myasthenic patient for any operative procedure?
28 Review the anesthetic concerns for a patient with Lambert-Eaton syndrome
KEY POINTS: Malignant Hyperthermia and Other Motor Diseases
1. Bhatt J.R., Pascuzzi R.M. Neuromuscular disorders in clinical practice: case studies. Neurol Clin. 2006;24:233-265.
2. Brambrink A.M., Kirsch J.R. Perioperative care of patients with neuromuscular disease and dysfunction. Anesthesiol Clin. 2007;25:483-509.
3. Brandom B.W. The genetics of malignant hyperthermia. Anesthesiol Clin North Am. 2005;23:615-619.
4. Burkman J.M., Posner K.L., Domino K.B. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology. 2007;106:901-906.
5. Larach M.G., Brandom B.W., Allen G.C., et al. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006. Anesthesiology. 2008;108:603-611.